Dr Reddy's joins hands with Gland Pharma to mkt 8 ANDAs in US

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Dr Reddy's Laboratories on Wednesday said it has entered into a collaboration with Gland Pharma to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs) in the US market.

Gland Pharma is a city-based developer and manufacturer of sterile dosage forms.

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and applications that will be filed imminently, and comprised generic injectables administered in hospitals and clinics in America, Dr Reddy's said in a statement.

"Our strengths, combined with Gland's track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our speciality injectables offering in the short-to-medium term," Alok Sonig, Executive Vice President and Head of North America said.

Dr Reddy's is developing its injectable business in the US and recently launched Paricalcitol injection, a therapeutic equivalent generic version of Zemplar there. PTI GDK RR inistration (USFDA) and applications that will be filed imminently, and comprised generic injectables administered in hospitals and clinics in America, Dr Reddy's said in a statement.

"Our strengths, combined with Gland's track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our speciality injectables offering in the short-to-medium term," Alok Sonig, Executive Vice President and Head of North America said.

Dr Reddy's is developing its injectable business in the US and recently launched Paricalcitol injection, a therapeutic equivalent generic version of Zemplar there.